The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
About this item
Full title
Author / Creator
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC. Therefore, we investigated the correlation between the change ra...
Alternative Titles
Full title
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a3db878031ea47dc9a5602705cc07dcf
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a3db878031ea47dc9a5602705cc07dcf
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-022-10002-x
